What is “Trilaciclib patent spiro” likely referring to?
“Trilaciclib” is the drug name; “spiro” usually points to a specific chemical structure motif (a spirocyclic ring system). In patent searches, people often combine the drug name with a structure keyword like “spiro” to find claims or examples that use spiro compounds. With only the provided prompt, the exact patent number, assignee, or the specific “spiro” claim isn’t identifiable.
How do people find trilaciclib patents using “spiro” as a search term?
Patent databases (such as Google Patents, Espacenet, or the USPTO) allow searching for:
- Keyword text in claims/specifications (e.g., “spiro”)
- Chemical descriptors and substructures (more advanced)
- The drug name (e.g., “trilaciclib” or alternate spellings)
- Assignee/inventor names (often faster once you know the parties)
A common workflow is to start broad with: trilaciclib + spiro, then narrow by assignee and by the claim language (for example, “spiro” appearing in examples vs. claims).
Why does the “spiro” structure matter for patentability?
Patent disputes and claim scope often hinge on whether a competitor’s compound uses:
- The same core scaffold (including spirocyclic features)
- The same substituents and linkers
- The same biological target/indication language and test data requirements
- The same mechanism (trilaciclib is generally associated with protecting normal cells during chemo by targeting cell cycle regulation pathways), which can show up in patent claim categories
If a patent’s independent claims explicitly require a spirocyclic moiety, then a non-spiro alternative may fall outside those claims, depending on how broadly the patent is drafted.
Which trilaciclib patents are commonly searched (and what “spiro” would connect to)?
People typically search for:
- Composition-of-matter patents covering specific chemical entities (where “spiro” is most relevant)
- Method-of-use patents for treatment regimens/indications
- Formulation/process patents (which may mention chemical building blocks but might not emphasize “spiro” in the claims)
“Spiro” is most likely to appear in composition-of-matter content (compound examples and related claims), not in broad clinical/regimen method claims.
What I need from you to answer precisely
To identify the exact trilaciclib “spiro” patent (and summarize what it claims), send one of the following:
- A patent number (e.g., US…, EP…, WO…)
- A link to the patent record
- The assignee/company name and the year
- The exact phrase you saw (e.g., “spiro [compound name]” or a snippet of claim text)
Once you provide that, I can tell you which spirocyclic feature the patent covers, what the claims require, and how that could affect freedom-to-operate or generic/biosimilar-style challenges (depending on the patent type and jurisdiction).